65,437 trials
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Post Operative Cognitive Dysfunction · Emergence From Anesthesia
Primary: Number of Participants With Adverse Events — 0; 0 Participants
Leukemia · Lymphoma
Primary: Number of Patients Who Received 2 Doses of Natural Killer (NK) Cell Infusions — 3; 2; 5 Participants
Cesarean Section · Supplemental Oxygen · Umbilical Cord Gases
Primary: Umbilical Cord pH Levels — 7.29; 7.28 pH
Operative Surgical Procedures
Primary: Acceptable View of the Glottic Aperature (Grade I-II) — 20; 21 participants
Wounded Warrior · Limb Shortening · Amputation
Primary: Efficacy of Autologous Fat Transfer at Pain Modulation at Respective Amputation Sites — 1.3; 0 score on a scale
Fecal Incontinence · Neurogenic Bowel
Primary: Fecal Soiling - Number of Participants That Gained and Maintained Continence on Each Flushing Regimen — 1; 4 Participants
Nephrolithiasis · Urinary Tract Infections
Primary: Number of Participants That Developed Sepsis After Surgery — 5; 6 Participants
Schizophrenia
Primary: Change From Baseline to Week 48 in the PANSS Total Score — -38.5 Units on a scale
UTI - Lower Urinary Tract Infection · Antibiotic Resistant Infection
Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants
Metastatic Soft Tissue Sarcoma
Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562
Pre-hypertension · Hypertension
Primary: Aortic Systolic Blood Pressure (SBP) — 112.7; 107.7; 106.2; 106.6 mm Hg
Melanoma
Primary: Best Overall Objective Response Rate (ORR) Within 24 Weeks Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 0.375 proportion of participants
Bladder Cancer
Primary: Percentage of Patients Without Distant Metastases by Three Years — 77.8; 84.0 percentage of participants
Sleep
Primary: Sleep Duration — -0.91; -2.93 minutes/night — p=0.932